{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T16:30:24Z","timestamp":1769013024623,"version":"3.49.0"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T00:00:00Z","timestamp":1694995200000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005727","name":"Universidade de Coimbra","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005727","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Pharm. Investig."],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Amorphous solid dispersions (ASD) for nasal delivery offer the opportunity to increase drug release performance, while using polymers with mucoadhesive properties. The aim of the present study was to apply this solubility enhancement technique to a poorly soluble drug for nasal delivery, while comparing two particle engineering strategies, namely spray dried microparticles and chimeral agglomerates, with the corresponding physical blends with crystalline drug.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Formulations of piroxicam were manufactured using varied polymer and particle engineering strategies and evaluated through in vitro drug release and ex vivo permeation studies, as well as nasal deposition and in vivo pharmacokinetic studies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>ASD with hydroxypropyl methylcellulose (HPMC) showed enhanced drug release and permeation, compared to polyvinylpyrrolidone\/vinyl acetate formulations and blends. Nasal deposition of HPMC chimeral agglomerates suggested off-target deposition. In vivo pharmacokinetic studies revealed that spray-dried HPMC-containing microparticles exhibited the highest maximum plasma concentration (C<jats:sub>max<\/jats:sub>) and the lowest time to attain it (t<jats:sub>max<\/jats:sub>). In vitro release rate and in vivo absorption rate were correlated as well as t<jats:sub>max<\/jats:sub> and in vitro performance. When excluding the formulation with least nasal targeted deposition, in vitro release and ex vivo permeation performance were also correlated with C<jats:sub>max<\/jats:sub> and area under the drug concentration-time curve (AUC) from 0 to 1\u00a0h, with R<jats:sup>2<\/jats:sup>\u2009&gt;\u20090.89.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>ASD for nasal delivery provide fast drug absorption, which depends on the supersaturation ability of the polymer employed. In vitro-in vivo correlations suggested that in vitro release and ex vivo permeation studies are predictive tools regarding nasal absorption.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s40005-023-00630-1","type":"journal-article","created":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T07:02:21Z","timestamp":1695020541000},"page":"723-742","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Amorphous nasal powder advanced performance: in vitro\/ex vivo studies and correlation with in vivo pharmacokinetics"],"prefix":"10.1007","volume":"53","author":[{"given":"Patr\u00edcia","family":"Henriques","sequence":"first","affiliation":[]},{"given":"Joana","family":"Bicker","sequence":"additional","affiliation":[]},{"given":"Andreia","family":"Carona","sequence":"additional","affiliation":[]},{"given":"Margarida","family":"Miranda","sequence":"additional","affiliation":[]},{"given":"Carla","family":"Vitorino","sequence":"additional","affiliation":[]},{"given":"Slavom\u00edra","family":"Doktorovov\u00e1","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6981-6639","authenticated-orcid":false,"given":"Ana","family":"Fortuna","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2023,9,18]]},"reference":[{"key":"630_CR1","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1023\/A:1016212804288\/METRICS","volume":"12","author":"GL Amidon","year":"1995","unstructured":"Amidon GL, Lennern\u00e4s H, Shah VP, Crison JR (1995) A theoretical basis for a Biopharmaceutic Drug classification: the correlation of in Vitro Drug Product Dissolution and in vivo bioavailability. Pharm Res 12:413\u2013420. https:\/\/doi.org\/10.1023\/A:1016212804288\/METRICS","journal-title":"Pharm Res"},{"key":"630_CR2","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/J.IJPHARM.2012.09.049","volume":"440","author":"AG Balducci","year":"2013","unstructured":"Balducci AG, Ferraro L, Bortolotti F et al (2013) Antidiuretic effect of desmopressin chimera agglomerates by nasal administration in rats. Int J Pharm 440:154\u2013160. https:\/\/doi.org\/10.1016\/J.IJPHARM.2012.09.049","journal-title":"Int J Pharm"},{"key":"630_CR3","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/J.JCONREL.2018.03.003","volume":"276","author":"Q Bao","year":"2018","unstructured":"Bao Q, Newman B, Wang Y et al (2018) In vitro and ex vivo correlation of drug release from ophthalmic ointments. J Controlled Release 276:93\u2013101. https:\/\/doi.org\/10.1016\/J.JCONREL.2018.03.003","journal-title":"J Controlled Release"},{"key":"630_CR4","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/J.IJPHARM.2015.06.046","volume":"491","author":"C Bartos","year":"2015","unstructured":"Bartos C, Ambrus R, Sipos P et al (2015) Study of sodium hyaluronate-based intranasal formulations containing micro- or nanosized meloxicam particles. Int J Pharm 491:198\u2013207. https:\/\/doi.org\/10.1016\/J.IJPHARM.2015.06.046","journal-title":"Int J Pharm"},{"key":"630_CR5","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.1016\/j.xphs.2020.08.008","volume":"109","author":"H Bennett-Lenane","year":"2020","unstructured":"Bennett-Lenane H, O\u2019Shea JP, O\u2019Driscoll CM, Griffin BT (2020) A retrospective Biopharmaceutical analysis of > 800 approved oral drug products: are Drug Properties of Solid Dispersions and lipid-based formulations distinctive? J Pharm Sci 109:3248\u20133261. https:\/\/doi.org\/10.1016\/j.xphs.2020.08.008","journal-title":"J Pharm Sci"},{"key":"630_CR6","doi-asserted-by":"crossref","unstructured":"Bruschi ML (2015) Mathematical models of drug release. Strategies to modify the drug release from Pharmaceutical Systems. Elsevier, pp 63\u201386","DOI":"10.1016\/B978-0-08-100092-2.00005-9"},{"key":"630_CR7","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/J.JCONREL.2012.02.028","volume":"161","author":"F Buttini","year":"2012","unstructured":"Buttini F, Colombo P, Rossi A et al (2012) Particles and powders: tools of innovation for non-invasive drug administration. J Controlled Release 161:693\u2013702. https:\/\/doi.org\/10.1016\/J.JCONREL.2012.02.028","journal-title":"J Controlled Release"},{"key":"630_CR9","doi-asserted-by":"publisher","first-page":"119341","DOI":"10.1016\/J.IJPHARM.2020.119341","volume":"582","author":"JZ Chen","year":"2020","unstructured":"Chen JZ, Kiaee M, Martin AR, Finlay WH (2020) In vitro assessment of an idealized nose for nasal spray testing: comparison with regional deposition in realistic nasal replicas. Int J Pharm 582:119341. https:\/\/doi.org\/10.1016\/J.IJPHARM.2020.119341","journal-title":"Int J Pharm"},{"key":"630_CR8","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1007\/S11095-022-03388-7","volume":"39","author":"JZ Chen","year":"2022","unstructured":"Chen JZ, Finlay WH, Martin A (2022) In Vitro Regional Deposition of Nasal Sprays in an Idealized Nasal Inlet: comparison with in vivo Gamma Scintigraphy. Pharm Res 39:3021\u20133028. https:\/\/doi.org\/10.1007\/S11095-022-03388-7","journal-title":"Pharm Res"},{"key":"630_CR10","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/J.IJPHARM.2014.11.051","volume":"478","author":"W Cho","year":"2015","unstructured":"Cho W, Kim M-S, Jung M-S et al (2015) Design of salmon calcitonin particles for nasal delivery using spray-drying and novel supercritical fluid-assisted spray-drying processes. Int J Pharm 478:288\u2013296. https:\/\/doi.org\/10.1016\/J.IJPHARM.2014.11.051","journal-title":"Int J Pharm"},{"key":"630_CR12","unstructured":"Colombo P, Santi P, Bettini R et al (2005) Powder for nasal administration of drugs"},{"key":"630_CR11","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/J.IJPHARM.2016.07.002","volume":"514","author":"G Colombo","year":"2016","unstructured":"Colombo G, Bortolotti F, Chiapponi V et al (2016) Nasal powders of thalidomide for local treatment of nose bleeding in persons affected by hereditary hemorrhagic telangiectasia. Int J Pharm 514:229\u2013237. https:\/\/doi.org\/10.1016\/J.IJPHARM.2016.07.002","journal-title":"Int J Pharm"},{"key":"630_CR13","doi-asserted-by":"publisher","first-page":"121720","DOI":"10.1016\/J.IJPHARM.2022.121720","volume":"620","author":"S Cunha","year":"2022","unstructured":"Cunha S, Swedrowska M, Bellahnid Y et al (2022) Thermosensitive in situ hydrogels of rivastigmine-loaded lipid-based nanosystems for nose-to-brain delivery: characterisation, biocompatibility, and drug deposition studies. Int J Pharm 620:121720. https:\/\/doi.org\/10.1016\/J.IJPHARM.2022.121720","journal-title":"Int J Pharm"},{"key":"630_CR16","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.jare.2022.04.011","volume":"44","author":"D D\u2019Angelo","year":"2023","unstructured":"D\u2019Angelo D, Kooij S, Verhoeven F et al (2023) Fluorescence-enabled evaluation of nasal tract deposition and coverage of pharmaceutical formulations in a silicone nasal cast using an innovative spray device. J Adv Res 44:227\u2013232. https:\/\/doi.org\/10.1016\/j.jare.2022.04.011","journal-title":"J Adv Res"},{"key":"630_CR15","doi-asserted-by":"publisher","first-page":"4889","DOI":"10.1002\/JPS.21335","volume":"97","author":"A Dalpiaz","year":"2008","unstructured":"Dalpiaz A, Gavini E, Colombo G et al (2008) Brain uptake of an anti-ischemic agent by nasal administration of microparticles. J Pharm Sci 97:4889\u20134903. https:\/\/doi.org\/10.1002\/JPS.21335","journal-title":"J Pharm Sci"},{"key":"630_CR14","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/J.ANTIVIRAL.2015.09.013","volume":"123","author":"A Dalpiaz","year":"2015","unstructured":"Dalpiaz A, Fogagnolo M, Ferraro L et al (2015) Nasal chitosan microparticles target a zidovudine prodrug to brain HIV sanctuaries. Antiviral Res 123:146\u2013157. https:\/\/doi.org\/10.1016\/J.ANTIVIRAL.2015.09.013","journal-title":"Antiviral Res"},{"key":"630_CR17","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.powtec.2019.09.052","volume":"359","author":"R de Souza Lima","year":"2020","unstructured":"de Souza Lima R, R\u00e9 MI, Arlabosse P (2020) Drying droplet as a template for solid formation: a review. Powder Technol 359:161\u2013171. https:\/\/doi.org\/10.1016\/j.powtec.2019.09.052","journal-title":"Powder Technol"},{"key":"630_CR18","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/J.CARBPOL.2014.02.064","volume":"108","author":"E Elmowafy","year":"2014","unstructured":"Elmowafy E, Osman R, El-Shamy AEA, Awad GAS (2014) Nasal polysaccharides-glucose regulator microparticles: optimization, tolerability and antidiabetic activity in rats. Carbohydr Polym 108:257\u2013265. https:\/\/doi.org\/10.1016\/J.CARBPOL.2014.02.064","journal-title":"Carbohydr Polym"},{"key":"630_CR19","unstructured":"European Medicines Agency (2011) Guideline on bioanalytical method validation. https:\/\/www.ema.europa.eu\/en\/bioanalytical-method-validation-scientific-guideline. Accessed 24 Jun 2019"},{"key":"630_CR20","unstructured":"European Medicines Agency (2014) Guideline on quality of oral modified release products. https:\/\/www.ema.europa.eu\/en\/quality-oral-modified-release-products-scientific-guidelines. Accessed 7 Mar 2023"},{"key":"630_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/S11095-022-03442-4","volume":"1","author":"S Farinha","year":"2022","unstructured":"Farinha S, S\u00e1 JV, Lino PR et al (2022) Spray freeze drying of Biologics: a review and applications for Inhalation Delivery. Pharm Res 1:1\u201326. https:\/\/doi.org\/10.1007\/S11095-022-03442-4","journal-title":"Pharm Res"},{"key":"630_CR22","unstructured":"Food and Drug Administration (1989) FDA-Approved Drugs - Sprix. In: New Drug Application (NDA): 022382. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=BasicSearch.process. Accessed 26 Apr 2023"},{"key":"630_CR25","unstructured":"Food and Drug Administration (1997) Guidance for Industry - Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro\/In Vivo Correlations. https:\/\/www.fda.gov\/media\/70939\/download. Accessed 24 Jun 2019"},{"key":"630_CR23","unstructured":"Food and Drug Administration (2018) Bioanalytical Method Validation Guidance for Industry. https:\/\/www.fda.gov\/media\/70858\/download. Accessed 24 Jun 2019"},{"key":"630_CR24","unstructured":"Food and Drug Administration (2023) Inactive Ingredients for Approved Drug Products. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/iig\/index.cfm?event=BasicSearch.page. Accessed 8 May 2023"},{"key":"630_CR26","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/J.EJPB.2014.03.004","volume":"88","author":"A Fortuna","year":"2014","unstructured":"Fortuna A, Alves G, Serralheiro A et al (2014) Intranasal delivery of systemic-acting drugs: small-molecules and biomacromolecules. Eur J Pharm Biopharm 88:8\u201327. https:\/\/doi.org\/10.1016\/J.EJPB.2014.03.004","journal-title":"Eur J Pharm Biopharm"},{"key":"630_CR27","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S1773-2247(07)50094-8","volume":"17","author":"N Frans\u00e9n","year":"2007","unstructured":"Frans\u00e9n N, Espef\u00e4lt Westin U, Nystr\u00f6m C, Bj\u00f6rk E (2007) The in vitro transport of dihydroergotamine across porcine nasal respiratory and olfactory mucosa and the effect of a novel powder formulation. J Drug Deliv Sci Technol 17:267\u2013271. https:\/\/doi.org\/10.1016\/S1773-2247(07)50094-8","journal-title":"J Drug Deliv Sci Technol"},{"key":"630_CR28","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3390\/pharmaceutics12010079","volume":"12","author":"T Furubayashi","year":"2020","unstructured":"Furubayashi T, Inoue D, Nishiyama N et al (2020) Comparison of various cell lines and three-dimensional mucociliary tissue model systems to estimate drug permeability using an in vitro transport study to predict nasal drug absorption in rats. Pharmaceutics 12:79. https:\/\/doi.org\/10.3390\/pharmaceutics12010079","journal-title":"Pharmaceutics"},{"key":"630_CR29","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/J.IJPHARM.2005.09.013","volume":"307","author":"E Gavini","year":"2006","unstructured":"Gavini E, Hegge AB, Rassu G et al (2006) Nasal administration of carbamazepine using chitosan microspheres: in vitro\/in vivo studies. Int J Pharm 307:9\u201315. https:\/\/doi.org\/10.1016\/J.IJPHARM.2005.09.013","journal-title":"Int J Pharm"},{"key":"630_CR30","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1002\/JPS.22382","volume":"100","author":"E Gavini","year":"2011","unstructured":"Gavini E, Rassu G, Ferraro L et al (2011) Influence of Chitosan Glutamate on the in vivo intranasal absorption of Rokitamycin from Microspheres. J Pharm Sci 100:1488\u20131502. https:\/\/doi.org\/10.1002\/JPS.22382","journal-title":"J Pharm Sci"},{"key":"630_CR31","doi-asserted-by":"publisher","first-page":"809","DOI":"10.3390\/PHARMACEUTICS13060809","volume":"13","author":"P Gieszinger","year":"2021","unstructured":"Gieszinger P, Kiss T, Szab\u00f3-R\u00e9v\u00e9sz P, Ambrus R (2021) The development of an in vitro horizontal diffusion cell to monitor nasal powder penetration inline. Pharmaceutics 13:809. https:\/\/doi.org\/10.3390\/PHARMACEUTICS13060809","journal-title":"Pharmaceutics"},{"key":"630_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11095-020-02913-w","volume":"37","author":"L Gomes dos Reis","year":"2020","unstructured":"Gomes dos Reis L, Ghadiri M, Young P, Traini D (2020) Nasal powder formulation of Tranexamic Acid and Hyaluronic Acid for the treatment of Epistaxis. Pharm Res 37:1\u201314. https:\/\/doi.org\/10.1007\/s11095-020-02913-w","journal-title":"Pharm Res"},{"key":"630_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/J.IJPHARM.2016.09.086","volume":"515","author":"VSS Gon\u00e7alves","year":"2016","unstructured":"Gon\u00e7alves VSS, Matias AA, Poejo J et al (2016) Application of RPMI 2650 as a cell model to evaluate solid formulations for intranasal delivery of drugs. Int J Pharm 515:1\u201310. https:\/\/doi.org\/10.1016\/J.IJPHARM.2016.09.086","journal-title":"Int J Pharm"},{"key":"630_CR33","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.taap.2017.03.013","volume":"323","author":"D Gon\u00e7alves","year":"2017","unstructured":"Gon\u00e7alves D, Alves G, Fortuna A et al (2017) Pharmacokinetics of opicapone, a third-generation COMT inhibitor, after single and multiple oral administration: a comparative study in the rat. Toxicol Appl Pharmacol 323:9\u201315. https:\/\/doi.org\/10.1016\/j.taap.2017.03.013","journal-title":"Toxicol Appl Pharmacol"},{"key":"630_CR34","doi-asserted-by":"publisher","first-page":"120161","DOI":"10.1016\/j.ijpharm.2020.120161","volume":"593","author":"J Gon\u00e7alves","year":"2021","unstructured":"Gon\u00e7alves J, Silva S, Gouveia F et al (2021) A combo-strategy to improve brain delivery of antiepileptic drugs: Focus on BCRP and intranasal administration. Int J Pharm 593:120161. https:\/\/doi.org\/10.1016\/j.ijpharm.2020.120161","journal-title":"Int J Pharm"},{"key":"630_CR36","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/J.IJPHARM.2005.03.016","volume":"297","author":"HS Gwak","year":"2005","unstructured":"Gwak HS, Choi JS, Choi HK (2005) Enhanced bioavailability of piroxicam via salt formation with ethanolamines. Int J Pharm 297:156\u2013161. https:\/\/doi.org\/10.1016\/J.IJPHARM.2005.03.016","journal-title":"Int J Pharm"},{"key":"630_CR37","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S0014-827X(02)00004-6","volume":"58","author":"C Has\u00e7i\u00e7ek","year":"2003","unstructured":"Has\u00e7i\u00e7ek C, G\u00f6n\u00fcl N, Erk N (2003) Mucoadhesive microspheres containing gentamicin sulfate for nasal administration: preparation and in vitro characterization. Il Farmaco 58:11\u201316. https:\/\/doi.org\/10.1016\/S0014-827X(02)00004-6","journal-title":"Il Farmaco"},{"key":"630_CR39","first-page":"A7","volume":"34","author":"P Henriques","year":"2021","unstructured":"Henriques P, Marques J, Paisana M et al (2021) Benchmarking of particle engineering technologies for nasal powder manufacture. J Aerosol Med Pulm Drug Deliv 34:A7. https:\/\/ddl-conference.com\/ddl2020-christmas-lectures\/conference-papers\/benchmarking-of-particle-engineering-technologies-for-nasal-powder-manufacture\/","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"630_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/J.EJPB.2022.05.002","volume":"176","author":"P Henriques","year":"2022","unstructured":"Henriques P, Fortuna A, Doktorovov\u00e1 S (2022) Spray dried powders for nasal delivery: process and formulation considerations. Eur J Pharm Biopharm 176:1\u201320. https:\/\/doi.org\/10.1016\/J.EJPB.2022.05.002","journal-title":"Eur J Pharm Biopharm"},{"key":"630_CR733","doi-asserted-by":"publisher","unstructured":"Henriques P, Bicker J, Silva S, Doktorovov\u00e1 S, Fortuna A (2023 August) Nasal-PAMPA: a novel non-cell-based high throughput screening assay for prediction of nasal drug permeability. Int J Pharm 643:123252. https:\/\/doi.org\/10.1016\/j.ijpharm.2023.123252","DOI":"10.1016\/j.ijpharm.2023.123252"},{"key":"630_CR40","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ejps.2016.05.031","volume":"95","author":"T Horv\u00e1th","year":"2016","unstructured":"Horv\u00e1th T, Ambrus R, V\u00f6lgyi G et al (2016) Effect of solubility enhancement on nasal absorption of meloxicam. Eur J Pharm Sci 95:96\u2013102. https:\/\/doi.org\/10.1016\/j.ejps.2016.05.031","journal-title":"Eur J Pharm Sci"},{"key":"630_CR41","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/J.EJPS.2010.02.002","volume":"40","author":"Y Huh","year":"2010","unstructured":"Huh Y, Cho H-J, Yoon I-S et al (2010) Preparation and evaluation of spray-dried hyaluronic acid microspheres for intranasal delivery of fexofenadine hydrochloride. Eur J Pharm Sci 40:9\u201315. https:\/\/doi.org\/10.1016\/J.EJPS.2010.02.002","journal-title":"Eur J Pharm Sci"},{"key":"630_CR42","unstructured":"International Council For Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (2022) ICH guideline M10 on bioanalytical method validation and study sample analysis. https:\/\/www.ich.org\/page\/multidisciplinary-guidelines. Accessed 1 Mar 2023"},{"key":"630_CR43","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1080\/03639040801926063","volume":"34","author":"M Jug","year":"2008","unstructured":"Jug M, Be\u0107irevi\u0107-La\u0107an M (2008) Development of a cyclodextrin-based nasal delivery system for Lorazepam. Drug Dev Ind Pharm 34:817\u2013826. https:\/\/doi.org\/10.1080\/03639040801926063","journal-title":"Drug Dev Ind Pharm"},{"key":"630_CR44","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/J.JPBA.2017.06.072","volume":"147","author":"M Jug","year":"2018","unstructured":"Jug M, Hafner A, Lovri\u0107 J et al (2018) An overview of in vitro dissolution\/release methods for novel mucosal drug delivery systems. J Pharm Biomed Anal 147:350\u2013366. https:\/\/doi.org\/10.1016\/J.JPBA.2017.06.072","journal-title":"J Pharm Biomed Anal"},{"key":"630_CR45","first-page":"A4","volume":"32","author":"A J\u00fcptner","year":"2019","unstructured":"J\u00fcptner A, Sarrailh S, Scherlie\u00df R (2019) Spray dried powders for nasal application - influence of particle morphology and filling process on aerosol generation. J Aerosol Med Pulm Drug Deliv 32:A4\u2013A4","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"630_CR46","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/pharmaceutics12010014","volume":"12","author":"A J\u00fcptner","year":"2020","unstructured":"J\u00fcptner A, Scherlie\u00df R (2020) Spray dried formulations for inhalation\u2014meaningful characterisation of powder properties. Pharmaceutics 12:14. https:\/\/doi.org\/10.3390\/pharmaceutics12010014","journal-title":"Pharmaceutics"},{"key":"630_CR47","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1080\/07373937.2018.1545783","volume":"37","author":"B Juri\u0161i\u0107 Dukovski","year":"2019","unstructured":"Juri\u0161i\u0107 Dukovski B, Mrak L, Winnicka K et al (2019) Spray-dried nanoparticle-loaded pectin microspheres for dexamethasone nasal delivery. Drying Technol 37:1915\u20131925. https:\/\/doi.org\/10.1080\/07373937.2018.1545783","journal-title":"Drying Technol"},{"key":"630_CR48","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/J.MSEC.2015.11.028","volume":"59","author":"C Karavasili","year":"2016","unstructured":"Karavasili C, Bouropoulos N, Sygellou L et al (2016) PLGA\/DPPC\/trimethylchitosan spray-dried microparticles for the nasal delivery of ropinirole hydrochloride: in vitro, ex vivo and cytocompatibility assessment. Mater Sci Engineering: C 59:1053\u20131062. https:\/\/doi.org\/10.1016\/J.MSEC.2015.11.028","journal-title":"Mater Sci Engineering: C"},{"key":"630_CR49","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.compbiomed.2019.02.013","volume":"107","author":"M Kiaee","year":"2019","unstructured":"Kiaee M, Wachtel H, Noga ML et al (2019) An idealized geometry that mimics average nasal spray deposition in adults: a computational study. Comput Biol Med 107:206\u2013217. https:\/\/doi.org\/10.1016\/j.compbiomed.2019.02.013","journal-title":"Comput Biol Med"},{"key":"630_CR50","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1007\/S11095-011-0417-6\/FIGURES\/13","volume":"28","author":"V Kundoor","year":"2011","unstructured":"Kundoor V, Dalby RN (2011) Effect of formulation- and administration-related variables on deposition pattern of nasal spray pumps evaluated using a nasal cast. Pharm Res 28:1895\u20131904. https:\/\/doi.org\/10.1007\/S11095-011-0417-6\/FIGURES\/13","journal-title":"Pharm Res"},{"key":"630_CR51","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1089\/JAM.2004.17.335","volume":"17","author":"VA Marple","year":"2004","unstructured":"Marple VA, Olson BA, Santhanakrishnan K et al (2004) Next generation pharmaceutical impactor: a new impactor for pharmaceutical inhaler testing. Part III. Extension of archival calibration to 15 L\/min. J Aerosol Med 17:335\u2013343. https:\/\/doi.org\/10.1089\/JAM.2004.17.335","journal-title":"J Aerosol Med"},{"key":"630_CR52","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0169-409X(97)00059-8","volume":"29","author":"E Marttin","year":"1998","unstructured":"Marttin E, Schipper NGM, Verhoef JC, Merkus FWHM (1998) Nasal mucociliary clearance as a factor in nasal drug delivery. Adv Drug Deliv Rev 29:13\u201338. https:\/\/doi.org\/10.1016\/S0169-409X(97)00059-8","journal-title":"Adv Drug Deliv Rev"},{"key":"630_CR53","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3390\/PHARMACEUTICS2040339","volume":"2","author":"S Mirza","year":"2010","unstructured":"Mirza S, Miroshnyk I, Habib MJ et al (2010) Enhanced dissolution and oral bioavailability of Piroxicam Formulations: modulating effect of phospholipids. Pharmaceutics 2:339. https:\/\/doi.org\/10.3390\/PHARMACEUTICS2040339","journal-title":"Pharmaceutics"},{"key":"630_CR54","first-page":"441","volume":"1","author":"B Murphy","year":"2022","unstructured":"Murphy B, Aisenstat M, Ordoubadi M et al (2022) Intranasal Powder Administration of a spray-dried tuberculosis vaccine candidate characterized using the Alberta Idealized Nasal Inlet. Respiratory Drug Delivery 1:441\u2013446","journal-title":"Respiratory Drug Delivery"},{"key":"630_CR55","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0169-409X(97)00058-6","volume":"29","author":"N Mygind","year":"1998","unstructured":"Mygind N, Dahl R (1998) Anatomy, physiology and function of the nasal cavities in health and disease. Adv Drug Deliv Rev 29:3\u201312. https:\/\/doi.org\/10.1016\/S0169-409X(97)00058-6","journal-title":"Adv Drug Deliv Rev"},{"key":"630_CR56","volume-title":"Pharmaceutical amorphous solid dispersions","author":"A Newman","year":"2015","unstructured":"Newman A (2015) Pharmaceutical amorphous solid dispersions. John Wiley & Sons, Hoboken, New Jersey"},{"key":"630_CR58","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1021\/acs.molpharmaceut.1c00578","volume":"19","author":"PD Nunes","year":"2022","unstructured":"Nunes PD, Pinto JF, Henriques J, Paiva AM (2022) Insights into the release mechanisms of ITZ:HPMCAS Amorphous Solid Dispersions: the Role of Drug-Rich Colloids. Mol Pharm 19:51\u201366. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.1c00578","journal-title":"Mol Pharm"},{"key":"630_CR57","doi-asserted-by":"publisher","unstructured":"Nunes PD, Ferreira AF, Pinto JF et al (2023) In vitro Dissolution\/Permeation tools for amorphous solid dispersions bioavailability forecasting II: comparison and mechanistic insights. Eur J Pharm Sci 106513. https:\/\/doi.org\/10.1016\/j.ejps.2023.106513","DOI":"10.1016\/j.ejps.2023.106513"},{"key":"630_CR59","doi-asserted-by":"publisher","first-page":"121016","DOI":"10.1016\/J.IJPHARM.2021.121016","volume":"607","author":"P Papakyriakopoulou","year":"2021","unstructured":"Papakyriakopoulou P, Manta K, Kostantini C et al (2021) Nasal powders of quercetin-\u03b2-cyclodextrin derivatives complexes with mannitol\/lecithin microparticles for nose-to-brain delivery: in vitro and ex vivo evaluation. Int J Pharm 607:121016. https:\/\/doi.org\/10.1016\/J.IJPHARM.2021.121016","journal-title":"Int J Pharm"},{"key":"630_CR60","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1111\/J.2042-7158.2012.01523.X","volume":"64","author":"DJ Phillips","year":"2012","unstructured":"Phillips DJ, Pygall SR, Cooper VB, Mann JC (2012) Overcoming sink limitations in dissolution testing: a review of traditional methods and the potential utility of biphasic systems. J Pharm Pharmacol 64:1549\u20131559. https:\/\/doi.org\/10.1111\/J.2042-7158.2012.01523.X","journal-title":"J Pharm Pharmacol"},{"key":"630_CR61","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1080\/03639045.2017.1321659","volume":"43","author":"M Pozzoli","year":"2017","unstructured":"Pozzoli M, Traini D, Young PM et al (2017) Development of a Soluplus budesonide freeze-dried powder for nasal drug delivery. Drug Dev Ind Pharm 43:1510\u20131518. https:\/\/doi.org\/10.1080\/03639045.2017.1321659","journal-title":"Drug Dev Ind Pharm"},{"key":"630_CR62","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/J.IJPHARM.2018.11.072","volume":"556","author":"S Radivojev","year":"2019","unstructured":"Radivojev S, Zellnitz S, Paudel A, Fr\u00f6hlich E (2019) Searching for physiologically relevant in vitro dissolution techniques for orally inhaled drugs. Int J Pharm 556:45\u201356. https:\/\/doi.org\/10.1016\/J.IJPHARM.2018.11.072","journal-title":"Int J Pharm"},{"key":"630_CR63","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/J.IJPHARM.2005.02.006","volume":"295","author":"C Rasetti-Escargueil","year":"2005","unstructured":"Rasetti-Escargueil C, Grang\u00e9 V (2005) Pharmacokinetic profiles of two tablet formulations of piroxicam. Int J Pharm 295:129\u2013134. https:\/\/doi.org\/10.1016\/J.IJPHARM.2005.02.006","journal-title":"Int J Pharm"},{"key":"630_CR65","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/J.JCONREL.2015.01.025","volume":"201","author":"G Rassu","year":"2015","unstructured":"Rassu G, Soddu E, Cossu M et al (2015) Solid microparticles based on chitosan or methyl-\u03b2-cyclodextrin: a first formulative approach to increase the nose-to-brain transport of deferoxamine mesylate. J Controlled Release 201:68\u201377. https:\/\/doi.org\/10.1016\/J.JCONREL.2015.01.025","journal-title":"J Controlled Release"},{"key":"630_CR64","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3390\/pharmaceutics10040206","volume":"10","author":"G Rassu","year":"2018","unstructured":"Rassu G, Ferraro L, Pavan B et al (2018) The role of combined penetration enhancers in nasal microspheres on in vivo drug bioavailability. Pharmaceutics 10:206. https:\/\/doi.org\/10.3390\/pharmaceutics10040206","journal-title":"Pharmaceutics"},{"key":"630_CR66","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S1773-2247(04)50083-7","volume":"14","author":"P Russo","year":"2004","unstructured":"Russo P, Buttini F, Sonvico F et al (2004) Chimeral agglomerates of microparticles for the administration of caffeine nasal powders. J Drug Deliv Sci Technol 14:449\u2013454. https:\/\/doi.org\/10.1016\/S1773-2247(04)50083-7","journal-title":"J Drug Deliv Sci Technol"},{"key":"630_CR67","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1016\/j.addr.2005.07.003","volume":"57","author":"N Salamat-Miller","year":"2005","unstructured":"Salamat-Miller N, Chittchang M, Johnston TP (2005) The use of mucoadhesive polymers in buccal drug delivery. Adv Drug Deliv Rev 57:1666\u20131691","journal-title":"Adv Drug Deliv Rev"},{"key":"630_CR68","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/J.EJPS.2014.04.019","volume":"60","author":"A Serralheiro","year":"2014","unstructured":"Serralheiro A, Alves G, Fortuna A, Falc\u00e3o A (2014) Intranasal administration of carbamazepine to mice: a direct delivery pathway for brain targeting. Eur J Pharm Sci 60:32\u201339. https:\/\/doi.org\/10.1016\/J.EJPS.2014.04.019","journal-title":"Eur J Pharm Sci"},{"key":"630_CR69","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.jconrel.2015.09.052","volume":"219","author":"J Shen","year":"2015","unstructured":"Shen J, Burgess DJ (2015) In vitro-in vivo correlation for complex non-oral drug products: where do we stand? J Controlled Release 219:644\u2013651. https:\/\/doi.org\/10.1016\/j.jconrel.2015.09.052","journal-title":"J Controlled Release"},{"key":"630_CR70","doi-asserted-by":"publisher","first-page":"647","DOI":"10.3390\/pharmaceutics12070647","volume":"12","author":"A Sim\u00f5es","year":"2020","unstructured":"Sim\u00f5es A, Veiga F, Vitorino C (2020) Progressing towards the sustainable development of cream formulations. Pharmaceutics 12:647. https:\/\/doi.org\/10.3390\/pharmaceutics12070647","journal-title":"Pharmaceutics"},{"key":"630_CR71","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1016\/j.progpolymsci.2014.07.010","volume":"39","author":"A Sosnik","year":"2014","unstructured":"Sosnik A, Das Neves J, Sarmento B (2014) Mucoadhesive polymers in the design of nano-drug delivery systems for administration by non-parenteral routes: a review. Prog Polym Sci 39:2030\u20132075","journal-title":"Prog Polym Sci"},{"key":"630_CR72","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ejpb.2023.02.012","volume":"185","author":"S Suwabe","year":"2023","unstructured":"Suwabe S, Tagami T, Ogawa K, Ozeki T (2023) Improved drug transfer into brain tissue via the nose-to-brain approach using suspension or powder formulations based on the amorphous solid dispersion technique. Eur J Pharm Biopharm 185:137\u2013147. https:\/\/doi.org\/10.1016\/j.ejpb.2023.02.012","journal-title":"Eur J Pharm Biopharm"},{"key":"630_CR73","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/J.DDTEC.2018.03.002","volume":"27","author":"P Szab\u00f3-R\u00e9v\u00e9sz","year":"2018","unstructured":"Szab\u00f3-R\u00e9v\u00e9sz P (2018) Modifying the physicochemical properties of NSAIDs for nasal and pulmonary administration. Drug Discov Today Technol 27:87\u201393. https:\/\/doi.org\/10.1016\/J.DDTEC.2018.03.002","journal-title":"Drug Discov Today Technol"},{"key":"630_CR74","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1080\/10717540902764172","volume":"16","author":"C Tas","year":"2009","unstructured":"Tas C, Ozkan CK, Savaser A et al (2009) Nasal administration of metoclopramide from different dosage forms: in vitro, ex vivo, and in vivo evaluation. Drug Deliv 16:167\u2013175. https:\/\/doi.org\/10.1080\/10717540902764172","journal-title":"Drug Deliv"},{"key":"630_CR77","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/J.EJPS.2017.09.027","volume":"113","author":"L Tiozzo Fasiolo","year":"2018","unstructured":"Tiozzo Fasiolo L, Manniello MD, Tratta E et al (2018) Opportunity and challenges of nasal powders: drug formulation and delivery. Eur J Pharm Sci 113:2\u201317. https:\/\/doi.org\/10.1016\/J.EJPS.2017.09.027","journal-title":"Eur J Pharm Sci"},{"key":"630_CR76","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1080\/1061186X.2019.1574300","volume":"27","author":"L Tiozzo Fasiolo","year":"2019","unstructured":"Tiozzo Fasiolo L, Manniello MD, Bortolotti F et al (2019) Anti-inflammatory flurbiprofen nasal powders for nose-to-brain delivery in Alzheimer\u2019s disease. J Drug Target 27:984\u2013994. https:\/\/doi.org\/10.1080\/1061186X.2019.1574300","journal-title":"J Drug Target"},{"key":"630_CR75","doi-asserted-by":"publisher","first-page":"120827","DOI":"10.1016\/j.ijpharm.2021.120827","volume":"605","author":"L Tiozzo Fasiolo","year":"2021","unstructured":"Tiozzo Fasiolo L, Dario Manniello M, Banella S et al (2021) Flurbiprofen Sodium Microparticles and Soft Pellets for nose-to-brain delivery: serum and brain levels in rats after nasal insufflation. Int J Pharm 605:120827. https:\/\/doi.org\/10.1016\/j.ijpharm.2021.120827","journal-title":"Int J Pharm"},{"key":"630_CR78","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3390\/PHARMACEUTICS13030385","volume":"13","author":"M Trenkel","year":"2021","unstructured":"Trenkel M, Scherlie\u00df R (2021) Nasal powder formulations: In-Vitro Characterisation of the impact of powders on nasal Residence Time and sensory Effects. Pharmaceutics 13:385. https:\/\/doi.org\/10.3390\/PHARMACEUTICS13030385","journal-title":"Pharmaceutics"},{"key":"630_CR79","doi-asserted-by":"publisher","first-page":"122630","DOI":"10.1016\/J.IJPHARM.2023.122630","volume":"633","author":"M Trenkel","year":"2023","unstructured":"Trenkel M, Scherlie\u00df R (2023) Optimising nasal powder drug delivery \u2013 characterisation of the effect of excipients on drug absorption. Int J Pharm 633:122630. https:\/\/doi.org\/10.1016\/J.IJPHARM.2023.122630","journal-title":"Int J Pharm"},{"key":"630_CR80","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/J.POWTEC.2016.01.042","volume":"292","author":"S Trows","year":"2016","unstructured":"Trows S, Scherlie\u00df R (2016) Carrier-based dry powder formulation for nasal delivery of vaccines utilizing BSA as model drug. Powder Technol 292:223\u2013231. https:\/\/doi.org\/10.1016\/J.POWTEC.2016.01.042","journal-title":"Powder Technol"},{"key":"630_CR81","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1016\/J.ADDR.2005.07.009","volume":"57","author":"MI Ugwoke","year":"2005","unstructured":"Ugwoke MI, Agu RU, Verbeke N, Kinget R (2005) Nasal mucoadhesive drug delivery: background, applications, trends and future perspectives. Adv Drug Deliv Rev 57:1640\u20131665. https:\/\/doi.org\/10.1016\/J.ADDR.2005.07.009","journal-title":"Adv Drug Deliv Rev"},{"key":"630_CR88","unstructured":"USP-NF 601 Inhalation and Nasal Drug Products: Aerosols, Sprays, and Powders\u2014Performance Quality Tests. In: United States Pharmacopeia 43-NF38 2S"},{"key":"630_CR82","doi-asserted-by":"publisher","first-page":"3826","DOI":"10.1002\/jps.22214","volume":"99","author":"B Van Eerdenbrugh","year":"2010","unstructured":"Van Eerdenbrugh B, Baird JA, Taylor LS (2010) Crystallization tendency of active pharmaceutical ingredients following rapid solvent evaporation - classification and comparison with crystallization tendency from undercooled melts. J Pharm Sci 99:3826\u20133838. https:\/\/doi.org\/10.1002\/jps.22214","journal-title":"J Pharm Sci"},{"key":"630_CR83","doi-asserted-by":"crossref","unstructured":"Vig B, Morgen M (2017) Formulation, process development, and Scale-Up: spray-drying amorphous solid dispersions for insoluble drugs. Developing solid oral dosage forms, 2nd edn. Academic Press, pp 793\u2013820","DOI":"10.1016\/B978-0-12-802447-8.00030-3"},{"key":"630_CR84","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ejpb.2020.04.011","volume":"153","author":"C Vitorino","year":"2020","unstructured":"Vitorino C, Silva S, Gouveia F et al (2020) QbD-driven development of intranasal lipid nanoparticles for depression treatment. Eur J Pharm Biopharm 153:106\u2013120. https:\/\/doi.org\/10.1016\/j.ejpb.2020.04.011","journal-title":"Eur J Pharm Biopharm"},{"key":"630_CR86","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0928-0987(98)00023-2","volume":"7","author":"C Wadell","year":"1999","unstructured":"Wadell C, Bj\u00f6rk E, Camber O (1999) Nasal drug delivery\u2013evaluation of an in vitro model using porcine nasal mucosa. Eur J Pharm Sci 7:197\u2013206. https:\/\/doi.org\/10.1016\/S0928-0987(98)00023-2","journal-title":"Eur J Pharm Sci"},{"key":"630_CR85","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S0928-0987(02)00240-3","volume":"18","author":"C Wadell","year":"2003","unstructured":"Wadell C, Bj\u00f6rk E, Camber O (2003) Permeability of porcine nasal mucosa correlated with human nasal absorption. Eur J Pharm Sci 18:47\u201353. https:\/\/doi.org\/10.1016\/S0928-0987(02)00240-3","journal-title":"Eur J Pharm Sci"},{"key":"630_CR87","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1124\/PR.112.005660","volume":"65","author":"HD Williams","year":"2013","unstructured":"Williams HD, Trevaskis NL, Charman SA et al (2013) Strategies to address low drug solubility in Discovery and Development. Pharmacol Rev 65:315\u2013499. https:\/\/doi.org\/10.1124\/PR.112.005660","journal-title":"Pharmacol Rev"}],"container-title":["Journal of Pharmaceutical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40005-023-00630-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40005-023-00630-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40005-023-00630-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T07:21:09Z","timestamp":1695626469000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40005-023-00630-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":89,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["630"],"URL":"https:\/\/doi.org\/10.1007\/s40005-023-00630-1","relation":{},"ISSN":["2093-5552","2093-6214"],"issn-type":[{"value":"2093-5552","type":"print"},{"value":"2093-6214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"2 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal procedures were conducted in agreement with the international regulations of the European Directive (2010\/63\/EU) regarding the protection of laboratory animals used for scientific purposes and with the Portuguese law on animal welfare (Decree-Law 113\/2013). The experimental and care procedures were reviewed and approved by the Animal Welfare Board (ORBEA, 02-2021\u2014\u00d3rg\u00e3o Respons\u00e1vel pelo Bem-Estar Animal) at the Faculty of Pharmacy of the University of Coimbra and the Portuguese Directorate-General for Food and Veterinary (DGAV). This article does not contain any studies with human participants performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of Human and Animal Rights"}},{"value":"All authors (P. Henriques, J. Bicker, A. Carona, M. Miranda, C. Vitorino, S. Doktorovov\u00e1, and A. Fortuna) declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}